Von Willebrand factor - LFB

Drug Profile

Von Willebrand factor - LFB

Alternative Names: vWF SD-35-DH; Wilfactin; Willefact; Willfact

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator LFB
  • Developer AOP Orphan Pharmaceuticals AG; LFB
  • Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Proteins; Recombinant proteins
  • Mechanism of Action Von Willebrand factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Von Willebrand disease

Most Recent Events

  • 17 Apr 2015 The product is approved in Estonia, Hungary, Latvia, Lithuania, Sweden, Slovakia and Slovenia for Von Willebrand's disease
  • 11 Oct 2013 No development reported - Phase-II for Von Willebrand's disease in USA (Parenteral)
  • 03 Apr 2013 Launched for Von Willebrand's disease in Norway (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top